Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...
An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization in the EU for Anktiva to treat adults with ...
Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Hosted on MSN
New drug offers hope to bladder cancer patients
Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results